JP2020526581A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526581A5 JP2020526581A5 JP2020521493A JP2020521493A JP2020526581A5 JP 2020526581 A5 JP2020526581 A5 JP 2020526581A5 JP 2020521493 A JP2020521493 A JP 2020521493A JP 2020521493 A JP2020521493 A JP 2020521493A JP 2020526581 A5 JP2020526581 A5 JP 2020526581A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- bifidobacterium animalis
- lactis
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762528669P | 2017-07-05 | 2017-07-05 | |
| US62/528,669 | 2017-07-05 | ||
| PCT/US2018/040841 WO2019010255A1 (en) | 2017-07-05 | 2018-07-05 | COMPOSITIONS AND METHODS FOR TREATING CANCER USING BIFIDOBACTERIUM ANIMALIS SSP. LACTIS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526581A JP2020526581A (ja) | 2020-08-31 |
| JP2020526581A5 true JP2020526581A5 (enExample) | 2021-08-12 |
| JP7254786B2 JP7254786B2 (ja) | 2023-04-10 |
Family
ID=63036353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521493A Active JP7254786B2 (ja) | 2017-07-05 | 2018-07-05 | ビフィドバクテリウム・アニマリス亜種ラクティス（Ｂｉｆｉｄｏｂａｃｔｅｒｉｕｍ ａｎｉｍａｌｉｓ ｓｓｐ．ｌａｃｔｉｓ）を用いて癌を処置するための組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10792314B2 (enExample) |
| EP (1) | EP3648780A1 (enExample) |
| JP (1) | JP7254786B2 (enExample) |
| KR (1) | KR102563191B1 (enExample) |
| CN (1) | CN111356464A (enExample) |
| AR (1) | AR112328A1 (enExample) |
| AU (1) | AU2018298087A1 (enExample) |
| BR (1) | BR112019028301A2 (enExample) |
| CA (1) | CA3068757A1 (enExample) |
| MA (1) | MA51770A (enExample) |
| TW (1) | TW201906620A (enExample) |
| WO (1) | WO2019010255A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| WO2016196605A1 (en) * | 2015-06-01 | 2016-12-08 | The University Of Chicago | Treatment of cancer by manipulation of commensal microflora |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| IL265109B2 (en) | 2016-09-13 | 2024-05-01 | Allergan Inc | Stabilized non-protein clostridial toxin compositions |
| JP7212945B2 (ja) | 2017-05-22 | 2023-01-26 | フォーディー ファーマ リサーチ リミテッド | 細菌株を含む組成物 |
| TW201907931A (zh) | 2017-05-24 | 2019-03-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物 |
| WO2018229188A1 (en) | 2017-06-14 | 2018-12-20 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| MD3804737T2 (ro) | 2017-06-14 | 2022-10-31 | 4D Pharma Res Limited | Compoziții care conțin tulpini bacteriene |
| CN115813955A (zh) | 2017-06-14 | 2023-03-21 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
| TW201906620A (zh) | 2017-07-05 | 2019-02-16 | 美商艾弗洛生物科技股份有限公司 | 使用動物雙岐桿菌乳亞種 (bifidobacterium animalis ssp. lactis) 治療癌症之組合物及方法 |
| EP3768285A1 (en) | 2018-03-19 | 2021-01-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| CA3106139A1 (en) | 2018-07-16 | 2020-01-23 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| MA54161A (fr) | 2018-12-12 | 2022-03-23 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes parabacteroides pour le traitement du cancer |
| WO2020252144A1 (en) * | 2019-06-11 | 2020-12-17 | Evelo Biosciences, Inc. | Secreted microbial extracellular vesicles |
| WO2021022110A1 (en) | 2019-08-01 | 2021-02-04 | Evelo Biosciences, Inc. | Inducing immune effects using bacteria of the genus bifidobacterium |
| KR102357904B1 (ko) * | 2019-10-29 | 2022-02-04 | 경희대학교 산학협력단 | 항암용 금 나노입자 |
| CN112618577B (zh) * | 2020-12-15 | 2023-07-25 | 深圳君拓生物科技有限公司 | 动物双歧杆菌在提高肿瘤免疫治疗应答中的作用 |
| US20240124905A1 (en) * | 2021-01-26 | 2024-04-18 | Cb Therapeutics, Inc. | Recombinant Polyprenol Diphosphate Synthases |
| TW202304415A (zh) * | 2021-04-08 | 2023-02-01 | 美商艾弗洛生物科技股份有限公司 | 含有細菌的藥物製劑 |
| CN113368259B (zh) * | 2021-06-22 | 2022-07-22 | 海南大学 | 一种基于修饰细菌加载纳米药物的方法及其复合物和在治疗结肠癌中的应用 |
| US20230096810A1 (en) * | 2021-09-24 | 2023-03-30 | Johnson & Johnson Consumer Inc. | Dosage forms for the delivery of a probiotic |
| CN114028432A (zh) * | 2021-11-05 | 2022-02-11 | 上海市第十人民医院 | 双歧杆菌提升铂类化疗药物敏感性的药物新用途 |
| CN115363094A (zh) * | 2021-11-30 | 2022-11-22 | 内蒙古伊利实业集团股份有限公司 | 乳双歧杆菌bl-99在预防和/或改善胃炎中的应用 |
| CN114480229B (zh) * | 2022-04-15 | 2022-08-09 | 微康益生菌(苏州)股份有限公司 | 一种动物双歧杆菌乳亚种菌株wkb148及其产品与应用 |
| CN115216423B (zh) * | 2022-06-15 | 2023-04-25 | 南昌大学 | 一种动物双歧杆菌sf及其在医药和食品中的应用 |
| WO2025071560A1 (en) * | 2023-09-28 | 2025-04-03 | Rutgers, The State University Of New Jersey | Methods of diagnosing b cell malignancies, detecting b cell malignancy relapse, and treating thereof |
| CN117417866B (zh) * | 2023-10-27 | 2026-02-27 | 江南大学 | 一种产胆盐水解酶的动物双歧杆菌及其在新生儿黄疸中的应用 |
| CN117327632B (zh) * | 2023-12-01 | 2024-02-13 | 四川厌氧生物科技有限责任公司 | 一种动物双歧杆菌及其应用 |
| CN121046519B (zh) * | 2025-11-05 | 2026-03-20 | 中国食品发酵工业研究院有限公司 | 动物双歧杆菌乳亚种bl-99的活菌定量检测方法及其引物、探针、试剂盒与应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ID29150A (id) | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | Penggunaan lactobacillus salivarius |
| US20030092163A1 (en) | 2001-07-26 | 2003-05-15 | Collins John Kevin | Probiotic bifidobacterium strains |
| GB0307026D0 (en) | 2003-03-27 | 2003-04-30 | Rowett Res Inst | Bacterial supplement |
| EP1481681A1 (en) | 2003-05-30 | 2004-12-01 | Claudio De Simone | Lactic acid bacteria combination and compositions thereof |
| JP4683881B2 (ja) | 2003-08-27 | 2011-05-18 | 有限会社アーク技研 | 抗腫瘍活性剤 |
| GB0323039D0 (en) | 2003-10-01 | 2003-11-05 | Danisco | Method |
| EP1714660A1 (en) | 2005-04-21 | 2006-10-25 | N.V. Nutricia | Uronic acid and probiotics |
| WO2007140613A1 (en) | 2006-06-06 | 2007-12-13 | Mcgill University | Fermented milk product and use thereof |
| US20080069861A1 (en) | 2006-09-19 | 2008-03-20 | National Starch And Chemical Investment Holding Corporation | Probiotic/Non-Probiotic Combinations |
| EP1920782A1 (en) | 2006-11-10 | 2008-05-14 | Glycotope Gmbh | Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof |
| RU2473681C2 (ru) | 2007-03-28 | 2013-01-27 | Элиментари Хелт Лимитед | ПРОБИОТИЧЕСКИЙ ШТАММ Bifidobacterium longum, КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ТАКОЙ ШТАММ, И ЕГО ПРИМЕНЕНИЕ |
| RU2466185C2 (ru) | 2007-03-28 | 2012-11-10 | Элиментари Хелт Лимитед | ПРОБИОТИЧЕСКИЙ ШТАММ Bifidobacterium longum, ПРОБИОТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЯ ШТАММА Bifidobacterium longum |
| EP1997907A1 (en) | 2007-06-01 | 2008-12-03 | Friesland Brands B.V. | Bifidobacteria |
| HUP0700552A2 (en) | 2007-08-27 | 2009-03-30 | Janos Dr Feher | Method and composition inhibiting inflammation |
| ES2431572T3 (es) | 2007-10-20 | 2013-11-27 | Université de Liège | Especies bifidobacterianas |
| WO2009149149A1 (en) | 2008-06-04 | 2009-12-10 | Trustees Of Dartmouth College | Prevention or treatment of immune-relevant disease by modification of microfloral populations |
| RU2546251C2 (ru) | 2009-11-11 | 2015-04-10 | Алиментари Хелс Лимитед | Пробиотический штамм бифидобактерий |
| WO2012142605A1 (en) | 2011-04-15 | 2012-10-18 | Samaritan Health Services | Rapid recolonization deployment agent |
| AU2014239883B2 (en) * | 2013-03-14 | 2019-01-17 | Therabiome, Llc | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
| EP3033091B1 (en) | 2013-08-16 | 2022-09-07 | Versitech Limited | Probiotic composition and use thereof in the prevention and treatment of hepatocellular carcinoma |
| WO2015038731A1 (en) | 2013-09-12 | 2015-03-19 | The Johns Hopkins University | Biofilm formation to define risk for colon cancer |
| EP2876167A1 (en) | 2013-11-21 | 2015-05-27 | Institut Gustave Roussy | Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment |
| CA2946463A1 (en) | 2014-05-05 | 2015-11-12 | Giovanni Mogna | Therapy for use in the treatment of tumors, acquired immunodeficiency syndrome and leukemias by dual immune biostimulation |
| CN104224851B (zh) | 2014-08-15 | 2018-08-24 | 中国农业大学 | 动物双歧杆菌乳酸亚种CGMCC No.9273的应用 |
| MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| KR102735818B1 (ko) | 2015-01-23 | 2024-11-28 | 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 암 예방에서 단쇄 지방산의 용도 |
| WO2016172658A2 (en) | 2015-04-23 | 2016-10-27 | Kaleido Biosciences, Inc. | Microbiome regulators and related uses thereof |
| EP3964234A1 (en) | 2015-04-23 | 2022-03-09 | Kaleido Biosciences, Inc. | Glycan therapeutics and methods of treatment |
| WO2016196605A1 (en) | 2015-06-01 | 2016-12-08 | The University Of Chicago | Treatment of cancer by manipulation of commensal microflora |
| MD3650033T2 (ro) | 2015-06-15 | 2022-08-31 | 4D Pharma Res Ltd | Compoziții conţinând tulpini bacteriene |
| CN106110322A (zh) * | 2016-07-29 | 2016-11-16 | 安徽瀚海博兴生物技术有限公司 | 一种药物组合物及其在制备治疗癌症药物中的应用 |
| TW201906620A (zh) | 2017-07-05 | 2019-02-16 | 美商艾弗洛生物科技股份有限公司 | 使用動物雙岐桿菌乳亞種 (bifidobacterium animalis ssp. lactis) 治療癌症之組合物及方法 |
-
2018
- 2018-07-05 TW TW107123313A patent/TW201906620A/zh unknown
- 2018-07-05 KR KR1020207003258A patent/KR102563191B1/ko active Active
- 2018-07-05 CA CA3068757A patent/CA3068757A1/en active Pending
- 2018-07-05 AU AU2018298087A patent/AU2018298087A1/en not_active Abandoned
- 2018-07-05 CN CN201880057669.0A patent/CN111356464A/zh active Pending
- 2018-07-05 AR ARP180101879 patent/AR112328A1/es unknown
- 2018-07-05 JP JP2020521493A patent/JP7254786B2/ja active Active
- 2018-07-05 EP EP18746378.1A patent/EP3648780A1/en not_active Withdrawn
- 2018-07-05 MA MA051770A patent/MA51770A/fr unknown
- 2018-07-05 WO PCT/US2018/040841 patent/WO2019010255A1/en not_active Ceased
- 2018-07-05 US US16/027,684 patent/US10792314B2/en not_active Expired - Fee Related
- 2018-07-05 BR BR112019028301-3A patent/BR112019028301A2/pt not_active IP Right Cessation
-
2019
- 2019-04-05 US US16/376,253 patent/US10576111B2/en not_active Expired - Fee Related
-
2020
- 2020-08-26 US US17/003,640 patent/US20210093680A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021502964A5 (enExample) | ||
| JP2021512133A5 (enExample) | ||
| AU2022231653B2 (en) | Diagnostic methods for t cell therapy | |
| JP7238030B2 (ja) | Ｔ細胞療法のために患者をコンディショニングする方法 | |
| US12157762B2 (en) | Tethered interleukin-15 and interleukin-21 | |
| CA3068757A1 (en) | Compositions and methods of treating cancer using bifidobacterium animalis ssp. lactis | |
| You et al. | Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells | |
| JP2020525758A (ja) | 免疫チェックポイント阻害薬によるがん治療に対する個別化応答の予測方法およびそのためのキット | |
| JP2019529565A (ja) | 養子細胞治療の方法 | |
| WO2021022110A1 (en) | Inducing immune effects using bacteria of the genus bifidobacterium | |
| CN118695868A (zh) | 包含il-10的双细胞因子融合蛋白与过继细胞疗法或双特异性t细胞衔接器用于治疗癌症 | |
| CN116323648A (zh) | 用于细胞工程改造和治疗的合成寡聚化系统 | |
| EP1753452B1 (en) | A method for altering the cd4/cd8 ratio and the mononuclear cellular infiltrate into a tumor | |
| JP2021524455A (ja) | Ｃｍｖ感染症及びｃｍｖ関連疾患に対する養子ｔ細胞療法 | |
| CN117917438A (zh) | 抗体融合蛋白及其制备和应用 | |
| Hermann et al. | Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects | |
| TW201938196A (zh) | 融合蛋白擴展 | |
| KR20240073042A (ko) | 인터루킨-7(il-7) 폴리펩티드를 코딩하는 종양용리성 바이러스 벡터 | |
| US20080131396A1 (en) | Method for altering the CD4/CD8 ratio and the mononuclear cellular infiltrate into a tumor | |
| Jindal et al. | The emerging role of cytokines in breast cancer: from initiation to survivorship | |
| Nijhof | Improving Chimeric Antigen Receptor (CAR) T cell therapy for solid tumours: Breaking down the suppressive barrier of the tumour microenvironment | |
| WO2025207491A1 (en) | Compositions and methods for cancer immunotherapy | |
| HK40097120A (en) | Diagnostic methods for t cell therapy | |
| CN116490205A (zh) | 使用沙粒病毒载体的癌症治疗策略 | |
| Strome et al. | Reassessment of CD62L as a marker of pre-effector T cells in the tumor draining lymph nodes of head and neck cancer patients |